Endothelial barrier is everything BRIEFLY IN FINNISH ABOUT US DRUG TARGETS PIPELINE NEWS INVESTOR RELATIONS CONTACT ‹ › Lean Drug Development Company Faron is a drug discovery and development company focussed on creating novel treatments for medical conditions with significant unmet needs. The company is based in Turku, Finland. Faron currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. READ ON › TRAUMAKINE Phase III study targeting the treatment of ARDS Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 30–45% mortality rate. READ ON › Faron raising approximately £8.0 million through a Placing and Subscription READ RESULTS › Recent news 21.9.2016 Results of Placing and Subscription, Issue of Equity and Director/PDMR Shareholding TURKU – FINLAND, 21 September 2016 – Faron Pharmaceuticals Oy (“Faron” or "Company") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce that following the announcement on 20 September 2016, the proposed Placing and Subscription has now conditionally completed. 20.9.2016 Proposed Placing and Subscription to raise £8.0 million TURKU – FINLAND, 20 September 2016 – Faron Pharmaceuticals Oy (“Faron” or "Company") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce a proposed placing of up to 2,868,000 new ordinary shares in the capital of the Company (the "Placing Shares") and a proposed subscription of up to 332,000 new ordinary shares in the capital of the Company (the “Subscription Shares”) at a price of 250 pence per share (the "Issue Price") to raise, in aggregate, up to approximately £8.0 million before expenses. 5.9.2016 Interim Results for the six months ended 30 June 2016 Progress continued in Traumakine® Phase III and with Clevegen® indications extended VIEW MORE › Stay updated! Subscribe now Keep updated with Company news and events. YOUR EMAIL ADDRESS Traumakine video Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial. PRINT SHARE FOLLOW US ON LINKED IN Faron Pharmaceuticals Joukahaisenkatu 6, Intelligate FIN-20520 TURKU Finland Phone: +358 2 469 5151 Fax: +358 2 469 5152 Email: info@faronpharmaceuticals.com